ICON has been selected by Bristol-Myers Squibb as a preferred provider for full-service clinical pharmacology and exploratory clinical studies. ICON also provides global support for BMS’ clinical development pipeline, per the companies’ June 2010 agreement. ICON will provide a broad range of early phase services from its Clinical Pharmacology Units in San Antonio, TX, Omaha, NE, and Manchester, UK, as well as scientific services such as protocol design and development, project management,...